Long-Term Immunogenicity and Efficacy of Hepatitis B Vaccine in Homosexual Men

New England Journal of Medicine

Volumn 315, Issue 4, 1986, Pages 209-214

  Hadler, Stephen C ^a,b,c,d   Francis, Donald P ^a,b,c,d   Maynard, James E ^a,b,c,d   Thompson, Sumner E ^a,b,c,d   Judson, Franklyn N ^a,b,c,d   Echenberg, Dean F ^a,b,c,d   Ostrow, David G ^a,b,c,d   O'malley, Paul M ^a,b,c,d   Penley, Kent A ^a,b,c,d   Altman, Norman L ^a,b,c,d   Braff, Erwin ^a,b,c,d   Shipman, Gregory F ^a,b,c,d   Coleman, Patrick J ^a,b,c,d   Mandel, Eric J ^a,b,c,d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Bureau of Communicable Disease Control ^*  (United States)

^c Denver Disease Control Service   (United States)

^d NW University Medical School   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INACTIVATED VIRUS VACCINE; PLACEBO;

ANTIBODY RESPONSE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG THERAPY; HEPATITIS B VIRUS; HOMOSEXUALITY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LIVER; PREVENTION; PRIORITY JOURNAL; THERAPY; VACCINATION;

EID: 0022655463     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198607243150401     Document Type: Article

References (12)

1. Szmuness W. Stevens CE, Zang EA, Harley EJ, Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1981; 1: 377–85.
2. Francis DP, Hadler SC, Thompson SE, et al. The prevention of hepatitis B with vaccine: report of the Centers for Disease Control multi-center efficacy trial among homosexual men. Ann Intern Med 1982; 97: 362–6.
3. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med 1982; 307: 1481–6.
4. Maupas P, Goudeau A, Coursaget P, Drucker F, Barin F, André M. Immunization against hepatitis B in man: a pilot study of two years' duration. In: Vyas GN, Cohen SN, Schmid R, eds. Viral hepatitis: a contemporary assessment of etiology, epidemiology, pathogenesis and prevention. Philadelphia: Franklin Institute Press, 1978:539–56.
5. Cròsnier J, Jungers P, Couroucé A-M, et al. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units. I. Medical staff. Lancet 1981; 1: 455–9.
6. Coutinho RA, Lelie N, Albrecht-van Lent P, et al. Efficacy of a heat inactivated hepatitis B vaccine in male homosexuals: outcome of a placebo controlled double blind trial. Br Med J 1983; 286: 1305–8.
7. Stevens CE, Taylor PE, Tong MJ, Toy PT, Vyas GN. Hepatitis B vaccine: an overview. In: Vyas GN, Dienstag JL, Hoofnagle JH, eds. Viral hepatitis and liver disease. Orlando: Grune & Stratton, 1984:275–91.
8. Hadler SC, Francis DP, Thompson SE, et al. Long term efficacy of hepatitis B vaccine. In: Vyas GN, Dienstag JL, Hoofnagle JH, eds. Viral hepatitis and liver disease. Orlando: Grune & Stratton, 1984:693. abstract.
9. Jilg W, Schmidt M, Deinhardt F, Zachoval R. Hepatitis B vaccination: how long does protection last? Lancet 1984; 2: 458.
10. McLean AA, Shaw R Jr. Hepatitis B virus vaccine. Ann Intern Med 1982; 97: 451.
11. Dienstag JL, Werner BG, Polk BF, et al. Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. Ann Intern Med 1984; 101: 34–40.
12. Jaffe HW, Darrow WW, Echenberg DF, et al. The acquired immunodeficiency syndrome in a cohort of homosexual men: a six-year follow-up study. Ann Intern Med 1985; 103: 210–4.